“明竹欣”联合治疗尖锐湿疣35例疗效观察

Effective Observation of MAXVIR Combined Therapy Treating 35 Cases of Condyloma Acuminatum

目的 评价“明竹欣”(盐酸万乃洛韦的商品名)治疗尖锐湿疣的有效性和安全性。方法 用随机活性对照方法,比较用高频电刀切除疣体后分别应用“明竹欣”(口服0.3克,1日2次,连续21日)和干扰素(周部注射1百万单位,1周2次,连续4周)治疗尖锐湿疣,明竹欣组和干扰素组各35例患者,治疗后随访1年。结果 明竹欣组治愈率为71.4％,干扰素组为65.7％,差异不显著(P>0.05),明竹欣组无明显不良反应。结论 明竹欣是一种高选择性和低毒性的抗病毒药物,患者有极好的顺应性,用它治疗尖锐湿疣有很好的疗效,值得临床应用。

Objective To evaluate the effectiveness and safety of MAXVIR (valaciclovir hydrochloride) treating condy-loma acuminatum (CA). Methods Randomization was used with active control. Each of the two groups, MAXVIR group and INF (interferon) group, was made up of thirty- five patients with CA. After the warts of CA being resected with high frequency electric lancet, the patients in MAXVIR group were administered by MAXVIR, 0.3g, bid, for 21 days. Those in the INF group were locally injected INF, 1MIU, twice a week for four weeks. A follow - up of one year was made after all patients being treated. Results The relief rates of MAXVIR group and INF group were 71.4% and 65.7%, respectively, which there was no significant difference (P>0.05). No severe adverse reaction happened in the MAXVIR group during the trial. Conclusion MAXVIR is an antiviral drug with high selection and low toxicity and, the patients always have a very good compliance; therefore, it is very effective and useful in clinical treatment of CA.